About this Event
Many cancer therapies, including CAR-T cells, T-cell engagers, antibody-drug conjugates, and monoclonal antibodies, work by recognising a specific marker (an antigen) on the surface of cancer cells. But how much of that marker a cell carries can make a big difference to whether the treatment actually works. Studying this relationship has traditionally been difficult, because it’s hard to get cells with a reliable, controllable range of marker levels to test against.
RoukenBio has developed IndEx-2, a cell-line platform that solves this problem. It allows scientists to precisely dial up or down the amount of a target marker (or even two markers at once) on a set of cells that are otherwise genetically identical, giving a controlled range to test therapies against. Using two plant-derived compounds to switch expression on and off, the platform lets researchers see exactly how much of a marker is needed before a treatment starts working, helping to predict which patients and tumours are most likely to respond.
Come along to hear more about how this platform is helping to accelerate the development of new cancer treatments.
Event venue & nearby stays
Innovation Gateway, The London Cancer Hub, Cotswold Road, Sutton, United Kingdom
Concerts, fests, parties, meetups — all the happenings, one place.